It was an ordinary surgery to remove a tumor — until doctors turned off the lights and the patient’s chest started to glow. A spot over his heart shined purplish pink. Another shimmered in a lung. They were hidden cancers revealed by fluorescent dye, an advance that could soon transform how hundreds of thousands of operations are done each year.
Surgery has long been the best way to cure cancer. If the disease recurs, it is usually because stray tumor cells were left behind or others lurked undetected, but there is no good way for surgeons to tell what is cancer and what is not. They look and feel for defects, but good and bad tissue often seem the same.
Now, dyes are being tested to make cancer cells light up so that doctors can cut them out and give patients a better shot at survival.
Illustration: Mountain People
With dyes, “it’s almost like we have bionic vision,” said Sunil Singhal, a doctor at the University of Pennsylvania. “We can be sure that we’re not taking too much or too little.”
The dyes are experimental, but advancing quickly. Two are in late-stage studies aimed at winning US Food and Drug Administration approval.
Johnson & Johnson just invested US$40 million into one and US federal grants support some of the work.
“We think that this is so important. Patients’ lives will be improved by this,” said Paula Jacobs, an imaging expert at the US National Cancer Institute.
In about five years, “there will be a palette of these,” she said.
Singhal was inspired a decade ago, while pondering a student who died when her lung cancer recurred soon after he thought that he had removed it all. He was lying next to his baby, gazing up at fluorescent decals.
“I looked up and saw all these stars on the ceiling and I thought, how cool if we could make cells light up” so people would not die from unseen tumors, he said.
A dye called Indocyanine green had long been used for various medical purposes. Singhal found that when big doses were given by intravenous therapy a day before surgery, it collected in cancer cells and glowed when exposed to near infrared light. He dubbed it TumorGlow and has been testing it for lung, brain and other tumor types.
He used it on Ryan Ciccozzi, a 45-year-old highway worker and father of four from Deptford, New Jersey, and found hidden cancer near Ciccozzi’s heart and in a lung.
“The tumor was kind of growing into everything in there,” Ciccozzi said. “Without the dye, I don’t think that they would have seen anything” besides the baseball-sized mass visible on CT scans.
Singhal is also testing a dye for On Target Laboratories, based in a Purdue research park in Indiana, that binds to a protein more common in cancer cells. A late-stage study is underway for ovarian cancer and a mid-stage one for lung cancer.
In one study, the dye highlighted 56 of 59 lung cancers seen on scans before surgery, plus nine more that were not visible ahead of time.
Each year, about 80,000 patients in the US have surgery for suspicious lung spots.
If a dye could show that the cancer was confined to a small node, the surgeons could remove a wedge instead of a whole lobe and preserve more breathing capacity, On Target chief executive officer Marty Low said.
No price has been set, but dyes are cheap to make and the cost should fit within rates that hospitals negotiate with insurers for these operations, he said.
Dyes might hold the most promise for breast cancer, said Len Lichtenfeld, a doctor with the American Cancer Society.
Up to one-third of women who have a lump removed need a second operation because margins were not clear — an edge of the removed tissue later was found to harbor cancer.
“If we could drop that down into the single digits, the impact would be huge,” said Kelly Londy, who heads Lumicell, a suburban Boston company testing a dye paired with a device to scan the lump cavity for stray cancer cells.
A device called MarginProbe is sold now, but it uses different technology to examine the surface of tissue that has been taken out, so it cannot pinpoint in the breast where residual disease lurks, said Barbara Smith, a breast surgeon at Massachusetts General Hospital.
She leads a late-stage study of Lumicell’s system in 400 breast cancer patients. In an earlier study of 60 women, it revealed all of the cancers, verified by tissue tests later.
However, it also gave false alarms in more than one-quarter of the cases — “there were some areas where normal tissue lit up a little bit,” Smith said. “Still, you would rather take a little extra tissue with the first surgery rather than missing something and have to go back.”
Blaze Bioscience is testing Tumor Paint, patented by company cofounder Jim Olson of the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital. It is a combo product — a molecule that binds to cancer and a dye to make it glow.
“You can see it down to a few dozen cells or a few hundred cells,” Olson said. “I’ve seen neurosurgeons come out of the operating room with a big smile on their face because they can see the cancer very clearly.”
Early-stage studies have been done for skin, brain and breast cancers in adults, and brain tumors in children.
Avelas Biosciences of San Diego has a similar approach: A dye attached to a molecule to carry it into tumor cells. The company is finishing early studies in breast cancer and plans more for colon, head and neck, ovarian and other types.
Cancer drugs have had a lot of attention, while ways to improve surgery have had far less, company president Carmine Stengone said.
“This was just an overlooked area, despite the high medical need,” Stengone said.
Saudi Arabian largesse is flooding Egypt’s cultural scene, but the reception is mixed. Some welcome new “cooperation” between two regional powerhouses, while others fear a hostile takeover by Riyadh. In Cairo, historically the cultural capital of the Arab world, Egyptian Minister of Culture Nevine al-Kilany recently hosted Saudi Arabian General Entertainment Authority chairman Turki al-Sheikh. The deep-pocketed al-Sheikh has emerged as a Medici-like patron for Egypt’s cultural elite, courted by Cairo’s top talent to produce a slew of forthcoming films. A new three-way agreement between al-Sheikh, Kilany and United Media Services — a multi-media conglomerate linked to state intelligence that owns much of
The US and other countries should take concrete steps to confront the threats from Beijing to avoid war, US Representative Mario Diaz-Balart said in an interview with Voice of America on March 13. The US should use “every diplomatic economic tool at our disposal to treat China as what it is... to avoid war,” Diaz-Balart said. Giving an example of what the US could do, he said that it has to be more aggressive in its military sales to Taiwan. Actions by cross-party US lawmakers in the past few years such as meeting with Taiwanese officials in Washington and Taipei, and
Denmark’s “one China” policy more and more resembles Beijing’s “one China” principle. At least, this is how things appear. In recent interactions with the Danish state, such as applying for residency permits, a Taiwanese’s nationality would be listed as “China.” That designation occurs for a Taiwanese student coming to Denmark or a Danish citizen arriving in Denmark with, for example, their Taiwanese partner. Details of this were published on Sunday in an article in the Danish daily Berlingske written by Alexander Sjoberg and Tobias Reinwald. The pretext for this new practice is that Denmark does not recognize Taiwan as a state under
The Republic of China (ROC) on Taiwan has no official diplomatic allies in the EU. With the exception of the Vatican, it has no official allies in Europe at all. This does not prevent the ROC — Taiwan — from having close relations with EU member states and other European countries. The exact nature of the relationship does bear revisiting, if only to clarify what is a very complicated and sensitive idea, the details of which leave considerable room for misunderstanding, misrepresentation and disagreement. Only this week, President Tsai Ing-wen (蔡英文) received members of the European Parliament’s Delegation for Relations